Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Retained Earnings (2016 - 2025)

Historic Retained Earnings for Summit Therapeutics (SMMT) over the last 10 years, with Q3 2025 value amounting to -$2.1 billion.

  • Summit Therapeutics' Retained Earnings fell 7990.64% to -$2.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.1 billion, marking a year-over-year decrease of 7990.64%. This contributed to the annual value of -$1.2 billion for FY2024, which is 2228.17% down from last year.
  • As of Q3 2025, Summit Therapeutics' Retained Earnings stood at -$2.1 billion, which was down 7990.64% from -$1.8 billion recorded in Q2 2025.
  • Summit Therapeutics' 5-year Retained Earnings high stood at -$228.4 million for Q1 2021, and its period low was -$2.1 billion during Q3 2025.
  • Moreover, its 5-year median value for Retained Earnings was -$935.4 million (2023), whereas its average is -$839.6 million.
  • Its Retained Earnings has fluctuated over the past 5 years, first crashed by 18687.35% in 2023, then tumbled by 1260.17% in 2024.
  • Summit Therapeutics' Retained Earnings (Quarter) stood at -$299.5 million in 2021, then fell by 26.3% to -$378.3 million in 2022, then tumbled by 162.54% to -$993.3 million in 2023, then dropped by 22.28% to -$1.2 billion in 2024, then tumbled by 70.84% to -$2.1 billion in 2025.
  • Its Retained Earnings stands at -$2.1 billion for Q3 2025, versus -$1.8 billion for Q2 2025 and -$1.3 billion for Q1 2025.